Eukles Asset Management Sells 456 Shares of Masimo Co. (NASDAQ:MASI)

Eukles Asset Management reduced its position in shares of Masimo Co. (NASDAQ:MASI) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,864 shares of the medical equipment provider’s stock after selling 456 shares during the quarter. Eukles Asset Management’s holdings in Masimo were worth $1,039,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Massmutual Trust Co. FSB ADV increased its holdings in Masimo by 140.6% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the period. Byrne Asset Management LLC bought a new position in Masimo in the 4th quarter valued at about $28,000. NBC Securities Inc. bought a new position in Masimo in the 3rd quarter valued at about $34,000. Harel Insurance Investments & Financial Services Ltd. bought a new position in Masimo in the 4th quarter valued at about $36,000. Finally, Caisse DE Depot ET Placement DU Quebec bought a new position in Masimo in the 1st quarter valued at about $37,000. 85.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MASI has been the topic of a number of research analyst reports. StockNews.com upgraded shares of Masimo from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. Wells Fargo & Company upgraded shares of Masimo from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $117.00 to $160.00 in a research note on Monday, March 25th. BTIG Research raised their price target on shares of Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, March 25th. Stifel Nicolaus upgraded shares of Masimo from a “hold” rating to a “buy” rating and lifted their target price for the stock from $148.00 to $170.00 in a research report on Monday. Finally, Needham & Company LLC downgraded shares of Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Five analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, Masimo has a consensus rating of “Hold” and an average price target of $137.43.

Masimo Trading Down 0.9 %

Shares of NASDAQ:MASI traded down $1.22 during mid-day trading on Friday, hitting $134.70. The company had a trading volume of 114,697 shares, compared to its average volume of 573,745. The firm has a fifty day moving average price of $135.66 and a 200 day moving average price of $114.20. The company has a market capitalization of $7.13 billion, a PE ratio of 90.01 and a beta of 0.97. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.18 and a quick ratio of 1.22. Masimo Co. has a one year low of $75.22 and a one year high of $198.00.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.43. The company had revenue of $548.90 million during the quarter, compared to analyst estimates of $545.69 million. Masimo had a net margin of 3.98% and a return on equity of 13.77%. Masimo’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 EPS. As a group, research analysts forecast that Masimo Co. will post 3.51 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.